Showing results (171-180 of 229) with videos related to
Sort By:
Pageof 23
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 15, 2019
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with LymphomaNeeraj Y Saini, Rima M Saliba, Gabriela Rondon, et al.Journal for Immunotherapy of Cancer|November 18, 2018
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J Reilley, Patricia McCoon, Carl Cook, et al.British Journal of Haematology|June 20, 2014
Double hit lymphoma: the MD Anderson Cancer Center clinical experienceYasuhiro Oki, Mansoor Noorani, Pei Lin, et al.The Journal of Investigative Dermatology|December 10, 2021
miR-181a Promotes Multiple Protumorigenic Functions by Targeting TGFβR3Vida Chitsazzadeh, Tran N Nguyen, Alvaro de Mingo Pulido, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 7, 2017
Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor SelectionSatyajit Kosuri, Tara Wolff, Sean M Devlin, et al.Blood|February 10, 2019
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myelomaJunling Zhuang, Fazal Shirazi, Ram Kumar Singh, et al.British Journal of Haematology|March 18, 2020
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphomaNathan H Fowler, Loretta Nastoupil, Sven De Vos, et al.Leukemia|June 15, 2021
Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AMLYuki Nishida, Ran Zhao, Lauren E Heese, et al.Blood|June 25, 2017
Tonic B-cell receptor signaling in diffuse large B-cell lymphomaOndrej Havranek, Jingda Xu, Stefan Köhrer, et al.Leukemia & Lymphoma|August 9, 2021
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphomaLoretta J Nastoupil, Sattva S Neelapu, Richard Eric Davis, et al.Pageof 23